

RESECTABLE & BORDERLINE RESECTABLE

Clinical Trial Name: Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients with Localized Pancreatic Cancer (PANC Trial)

Study Design: This is a single arm, Phase II clinical trial utilizing neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic adenocarcinoma which utilizes a total neoadjuvant therapy approach with adaptive modification of the chemotherapy regimen based on radiographic response (CT scan), biochemical response (CA19-9 decline), and performance status (as measured by a short physical performance battery).

NCT#: NCT03322995	<p>Key Inclusion:</p> <ul style="list-style-type: none">ECOG performance status of < 2Histologically confirmed adenocarcinoma of the pancreasClinical stage resectable or borderline resectable pancreatic adenocarcinomaMust be CA19-9 producer (pretreatment CA19-9 > 35 U/mL when total bilirubin ≤ 2 mg/dL) <p>Key Exclusion:</p> <ul style="list-style-type: none">Received chemotherapy and/or radiation within 3 years prior to study enrollmentHistory of prior malignancy except for adequately treated in situ cancer of the cervix or basal cell or squamous cell skin cancer or localized prostate cancer with a normal PSA within the last 3 years
Study PI: Dr. Kathleen Christians	
Clinical Research Coordinator: Lauren Schmitz Phone: 414-805-5175	

Clinical Trial Name: PurlST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS SAmples Study (PANCREAS)

Study Design: This is an open-label, single arm, phase II study in patients with resectable and borderline resectable pancreatic cancer. The study intervention involves molecular profiling Purity Independent Subtyping of Tumors (PurlST) subtyping of pretreatment Endoscopic Ultrasound Fine Needle Aspiration (EUS/FNA) samples to determine pancreatic cancer subtype. Neoadjuvant therapy is directed based on the molecular subtype (classical vs. basal). Patients with classical subtype will receive a standard chemotherapy (mFOLFIRINOX) and patients with basal subtype will receive an alternative standard therapy (gemcitabine/nab-paclitaxel).

NCT#: NCT04683315	<p>Key Inclusion:</p> <p><i>Eligibility for screening consent:</i></p> <ul style="list-style-type: none">Suspicion of PDAC and plan for endoscopic biopsy or enough archival tissue to be requested from previous screening endoscopic biopsy.Agrees to additional EUS biopsy at the first restaging and tissue collection from surgical specimen <p><i>Eligibility for Treatment consent:</i></p> <ul style="list-style-type: none">ECOG performance status < 2Histologically confirmed adenocarcinoma. Biopsy must have been completed prior to start of treatmentClinical stage consistent with resectable or borderline resectable or locally advanced type A adenocarcinoma of the pancreas, based on CT or MRI findingsAdequate organ and bone marrow function, as defined by: total leukocytes >3 x10³/µL; ANC >1.5x 10³/µL; HgB >9 g/dL; platelets >100 x 10³/µL; creatinine clearance >60 mL/min or creatinine <1.5 mg/dL; bilirubin < 2 mg/dL; AST/SGOT & ALT/SGPT <3 x ULN <p>Key Exclusion:</p> <ul style="list-style-type: none">Received chemotherapy and/or radiation within three years prior to study enrollmentPrevious history of another malignancy w/in 3 years of study (other than cured basal or squamous cell carcinoma and other in situ carcinomas that were completely treated or localized prostate cancer with normal prostate specific antigen)
Study PI: Dr. Kathleen Christians	
Clinical Research Coordinator: Lauren Schmitz Phone: 414-805-5175	

Study Design: This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.

<p>NCT#: NCT06228599</p>	<p>Key Inclusion:</p> <ul style="list-style-type: none">• Pathologically confirmed pancreatic cancer (excluding neuroendocrine histology).• Pancreatic tumor is surgically removed and<ul style="list-style-type: none">◦ Patient has received multimodal therapy (neoadjuvant, sandwich or adjuvant chemotherapy ± radiation) or◦ Patient is ineligible for or refuses multimodal therapy• Patient has one of the following:<ul style="list-style-type: none">◦ Post-surgical cancer antigen (CA) 19-9 elevation (> 35 U/mL at least 6 weeks post-surgical resection) in the setting of bilirubin < 2 mg/dL (unless bilirubin elevation is consistent with Gilbert's syndrome) OR◦ High-risk pathological features, defined as positive surgical margin or lymph node involvement in cancer.• Patient has no definitive measurable disease recurrence or metastatic disease at the time of first post-surgical imaging (in those with high-risk pathological features) or within four weeks of elevated CA 19-9 value as evidenced by appropriate imaging• Laboratory values:<ul style="list-style-type: none">◦ Absolute neutrophil count (ANC) $\geq 1.0 \times 10^9/L$◦ Platelet count $\geq 75,000/mm^3$ ($125 \times 10^9/L$)◦ Hemoglobin (Hgb) $\geq 8 \text{ g/dL}$◦ aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT), alanine transaminase (ALT) serum glutamate-pyruvate transaminase (SGPT) $\leq 5 \times$ upper limit of normal range (ULN)◦ ECOG Performance Status < 3• At the time of treatment, patient should be off other anti-tumor agents for at least five half-lives of the agent or three weeks from the last day of treatment, whichever is shorter• Patient must be presented at the Molecular Tumor Board (MTB) and agree to receive the MTB-recommended therapy• Key Exclusion:<ul style="list-style-type: none">◦ CA 19-9 non-producers, unless high-risk pathological features present.◦ Receiving concomitant investigational agent(s) for pancreatic ductal adenocarcinoma (PDAC)◦ Radiographic evidence of metastatic disease◦ Inability to ingest study drugs by mouth◦ Diarrheal bowel movements > 6 per day postoperatively on maximal medical therapy◦ Patient has active, untreated, or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic intravenous therapy◦ Patient has undergone or planned major surgery other than diagnostic surgery (i.e., surgery done to obtain a biopsy for diagnosis without removal of an organ) within four weeks prior to Day 1 of study therapy◦ Uncontrolled concurrent illness, including, but not limited to, unstable angina pectoris, uncontrolled and clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
<p>Study PI: Dr. Mandana Kamgar</p>	
<p>Clinical Research Coordinator: Dawn Carini Phone: 414-805-0789</p>	

Clinical Trial Name: Promoting CT Engagement for Pancreatic Cancer With App (PROCLAIM)

Study Design: To develop a culturally tailored informational mobile application and test whether it will increase participation among Black pancreatic cancer subjects in clinical trial discussions with their care team. This project aims to identify and address barriers to enrollment of Black subjects in pancreatic cancer clinical trials using a culturally informed mobile health application to promote participation.

NCT#: NCT06252545

Study PI:
Dr. Ugwuji Madeuekwe

Clinical Research Coordinator:
Elizabeth Jeanes
Phone: 414-955-6806

Key Inclusion:

- Participants must meet the following inclusion criteria in order to participate in communication & education interview component of the study:
 - Informed consent obtained to participate in the study
 - 18 years or older
 - English speaking
 - Able and willing to participate in a 1-hour interview
 - History of pancreatic cancer diagnosis
 - Identify as Black

Key Exclusion:

- Inability to read and speak English
- Dementia altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent as determined by the study physician.